1[1]Bhardwaj N, Young J W, Nisanian A J, et al. Small amounts of superantigen, when presented on dendritic cells, are sufficient to initiate T cell responses. J Exp Med, 1993,178(2): 633-642.
2[2]Young J W, Steinman R M. The hematopoietic development of dendritic cells: a dstinct pathway for myeloid differentiation. Stem Cells, 1996, 14(4): 376-387.
3[3]Thomas R, Davis L S, Lipsky P E. Comparative accessory cell function of human eripheral blood dendritic cells and monocytes. J Immunol, 1993, 151(12): 6840-6852.
4[4]Steinman R M. Dendritic cells and immune-based therapies. Exp Hematol,1996, 24(8): 859-862.
5[5]Winzler C, Rovere P, Rescigno M, et al. Maturation stages of mouse dendriticcells in growth factor-dependent long-term cultures. J Exp Med,1997,185(2): 317-328.
6[6]Girolomoni G, Ricciardi-Castagnoli P. Dendritic cells hold promise for immuno therapy. Immunol Today,1997, 18(3): 102-104.
7[7]Lyman S D, James L, Vanden Bos T, et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell, 1993,75(6): 1157-167.
8[8]Yoo Y H, Park B S, Whitaker-Menezes D, et al. Dermal dendrocytes participate in the cellular pathology of experimental acute graft-versus-host disease. J Cutan Pathol,1998,25(8): 426-434.
9[9]Charbonnier A, Gaugler B, Sainty D,et al. Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias. Eur J Immunol,1999,29(8): 2567-2578.
10[10]Choudhury A, Gajewski J L, Liang J C, et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood,1997,15, 89(4): 1133-1142.
